Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ASPI files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Renergen Funding Uncertainty (new) — Filing identifies risk that Renergen may not receive or may face delays in funding from U.S. DFC or Standard Bank SA, critical for Virginia Gas Project development.
- Nasdaq Listing Risk (new) — Disclosure flags risks to ENDRA's continued Nasdaq listing before closing and combined company's ability to maintain listing post-merger.
- Tetra4 Loan Compliance (new) — Filing notes compliance risk with loan and credit facilities at Renergen subsidiary Tetra4, suggesting potential covenant or refinancing pressure.
ASP Isotopes to spin off Renergen helium unit via reverse merger with ENDRA, raising $50M
Filed June 25, 2026 · Period ending June 25, 2026 · ~2 min read
Key Changes
-
high
ASPI subsidiary Noble Africa will merge with ENDRA Life Sciences in a reverse merger, with Noble surviving. ASPI will contribute its Renergen helium subsidiary to Noble and retain ~89% ownership with 10-vote Class B shares, controlling the board (5 of 7 seats). Combined company to trade as Noble Africa Inc. (NOBA) on Nasdaq.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
high
Noble Africa secured $50M in private placement commitments at $6.57/unit, with ASPI investing $20M as lead investor and other investors (including $750K from ASPI executives and directors) contributing $30M. Financing closes immediately before merger, expected Q3-Q4 2026.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
medium
ASPI expanding its loan facility to Renergen to up to $200M and will provide ongoing admin services to the combined company for cost-plus fees. Post-merger agreements include helium sales and consolidated financial reporting requirements, maintaining operational ties.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
high
Dual-class structure gives ASPI 10 votes per Class B share versus 1 vote per Class A share. Class B shares convert to Class A on transfer except among ASPI affiliates. Economic rights equal across classes.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
medium
Transaction subject to SEC registration statement effectiveness, ENDRA stockholder approval, and customary closing conditions. Both boards have approved. ENDRA stockholders will own ~3% of combined company.
Item 8.01 — Other Events verify on EDGAR →
Summary
ASP Isotopes is executing a complex transaction to establish its Renergen helium subsidiary as a standalone public company. ASPI's wholly-owned subsidiary Noble Africa will merge with ENDRA Life Sciences in a reverse merger, with Noble surviving and renaming to Noble Africa Inc. (ticker NOBA).
ASPI will contribute its entire Renergen equity stake to Noble before closing and invest $20M of a concurrent $50M private placement, emerging with ~89% ownership and board control (5 of 7 directors). The dual-class structure grants ASPI 10 votes per Class B share, cementing control despite any future dilution. ENDRA stockholders receive only ~3% of the combined company.
The transaction addresses Renergen's capital needs for its Virginia Gas Project, a multi-phase helium and LNG development. However, the filing flags material execution risks: Renergen may not receive or may face delays in funding from the U.S. Development Finance Corporation or Standard Bank SA, both critical to project completion. Compliance risk with existing Tetra4 subsidiary debt and uncertainty around maintaining Nasdaq listing post-merger add further concerns. ASPI is also expanding its loan facility to Renergen to up to $200M and will provide ongoing admin services for cost-plus fees, maintaining financial and operational ties that blur the "spinoff" characterization. For ASPI shareholders, this creates a controlled subsidiary with significant funding risk and a structure that may limit minority investor influence in the new entity. Closing expected Q3-Q4 2026 pending SEC registration and ENDRA stockholder approval.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
ASP Isotopes announced execution of a merger agreement with ENDRA and subscription agreements involving Noble Investment and Renergen.
Added in current filing · verify on EDGAR →
On June 25, 2026, the Company and ENDRA issued a joint press release announcing the execution of the Merger Agreement and the Subscription Agreements.
ASP Isotopes and ENDRA executed a merger agreement and subscription agreements. The filing references a joint press release and an investor presentation prepared by Renergen in connection with a Noble Investment, but does not disclose transaction terms, consideration, or strategic rationale in the 8-K body itself.
Event · Item 3.02 — Unregistered Sales of Equity Securities
ASP Isotopes disclosed unregistered sales of equity securities (Units and Pre-Funded Warrants) under Section 4(a)(2) and Regulation D/S exemptions.
Added in current filing · verify on EDGAR →
The Units and the Pre-Funded Warrants, including the Class A Units underlying the Pre-Funded Warrants issuable in connection with the Subscription Agreements, were not or will not be registered under the Securities Act of 1933, as amended (the “Securities Act”) in reliance on the exemption from registration provided by Section 4(a) (2) of the Securities Act and/or Rule 506 of Regulation D promulgated thereunder or, for non-U.S. investors, Regulation S promulgated under the Securities Act.
The company sold Units and Pre-Funded Warrants (including underlying Class A Units) in a private placement without SEC registration, relying on exemptions for private offerings to accredited investors (Section 4(a)(2) and Regulation D Rule 506) and offshore sales to non-U.S. investors (Regulation S). The filing references Item 1.01 for transaction details, which are not included in this excerpt, so the number of securities sold, pricing, and proceeds raised are not disclosed here.
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 25, 2026, ASP Isotopes Inc., a Delaware corporation (“ASPI” or the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among ENDRA Life Sciences Inc., a Delaware corporation (“ENDRA”), Noble Africa LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of the Company (“Noble”), Renergen Limited, a company incorporated under the laws of the Republic of South Africa and a direct, wholly-owned subsidiary of the Company (“Renergen”), the Company, and Kruger Merger Sub LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of ENDRA (“Merger Sub”), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Noble (the “Merger”), with Noble surviving the Merger as a direct wholly-owned subsidiary of ENDRA (the “Surviving Company”).
ASPI's subsidiary Noble will merge into ENDRA Life Sciences in a reverse merger structure, with Noble surviving as ENDRA's wholly-owned subsidiary. ENDRA will rename itself Noble Africa Inc. and establish a dual-class stock structure. ASPI will contribute its Renergen subsidiary to Noble before the merger and receive Class B shares with 10 votes per share, giving ASPI significant voting control over the combined entity.
Added in current filing · verify on EDGAR →
Concurrently with the entry into the Merger Agreement, Noble entered into subscription agreements (“Subscription Agreements”) with the Company and certain investors pursuant to which Noble agreed to sell approximately (i) 4,594,218 Class A Units of Noble (“Class A Units”) and/or pre-funded warrants to purchase Class A Units of Noble (the “Pre-Funded Warrants”) to certain institutional investors and other persons and (ii) 3,054,185 Class B Units of Noble (“Class B Units” and, together with the Class A Units, the “Units”) to the Company, at a price per unit of $6.57 (or $6.57 less the Pre-Funded Warrant exercise price of $0.0001 for the Pre-Funded Warrants), for aggregate gross proceeds to Noble of approximately $50 million (the “Noble Investment”). Pursuant to the Subscription Agreements, the Noble Investment shall close immediately prior to the Merger.
Noble will raise approximately $50 million through the sale of Class A and Class B units at $6.57 per unit to institutional investors and ASPI itself. The capital raise will close immediately before the merger completes. ASPI executives including CEO Paul Mann ($500,003), COO Robert Ainscow ($100,002), and directors Robert Ryan ($100,002) and Duncan Moore ($49,998) are participating as investors.
Added in current filing · verify on EDGAR →
The A&R Certificate of Incorporation will authorize 1,000,000,000 shares of Class A Common Stock, 200,000,000 shares of Class B Common Stock, and 50,000,000 shares of preferred stock. Pursuant to the A&R Certificate of Incorporation, the holders of shares of Class A Common Stock and Class B Common Stock shall vote together as one class on all matters, with each holder of Class A Common Stock entitled to one vote for each share of Class A Common Stock held as of the applicable record date and each holder of Class B Common Stock entitled to ten votes for each share of Class B Common Stock held as of the applicable record date.
ENDRA will adopt a dual-class structure with Class A shares (1 vote each) and Class B shares (10 votes each). ASPI will receive Class B shares through its contribution of Renergen and its Noble Investment participation, giving it disproportionate voting power. Economic rights are equal between classes, but Class B shares convert to Class A upon transfer (except permitted transfers) or by majority Class B holder vote.
Added in current filing · verify on EDGAR →
Additionally, prior to the effective time of the Merger (the “Effective Time”), the Company will contribute all of its equity interest in Renergen to Noble in exchange for 55,500,000 of Noble’s Class B Units (the “Contribution”). The shares of Class B Common Stock (as defined below) received by the Company upon conversion of the Class B Units in connection with the Merger will entitle the Company to 10 votes per share on all matters submitted to a vote of the stockholders of ENDRA. ... At or prior to the Closing, the Company, ASPI South Africa Proprietary Limited, a wholly owned subsidiary of the Company (“ASPI SA”), and Renergen, shall enter into the fifth addendum to that certain ASPI Term Loan Facility, dated May 19, 2025, by and between the Company, ASPI SA and Renergen, pursuant to which the Company may provide loans to Renergen up to $200 million.
ASPI will contribute its entire equity interest in Renergen (a South African helium subsidiary) to Noble before the merger in exchange for 55.5 million Class B units. This contribution, combined with ASPI's Noble Investment purchase, will give ASPI substantial voting control through high-vote Class B shares. Separately, ASPI is expanding its loan facility to Renergen to allow up to $200 million in loans, maintaining financial ties post-transaction.
Added in current filing · verify on EDGAR →
Immediately after the Effective Time, the Board is expected to consist of seven directors, of which (i) one is anticipated to be the Chief Executive Officer of the Surviving Company (the “CEO Director”), (ii) five are to be non-executive directors designated solely by Noble (the “Noble Directors”) and (iii) one is to be a non-executive director designated solely by ENDRA (the “ENDRA Director”). ... The master transaction agreement will contain key provisions relating to the conduct of future transactions and govern the ongoing relationship between the Company and ENDRA after the Closing, including sales of helium, certain indemnification obligations and a requirement for ENDRA to maintain the same auditor and fiscal year as the Company for so long as the Company is required to consolidate the financial statements of the Company under GAAP. Under the shared services and employee matters agreements, the Company will provide certain administrative services to ENDRA in exchange for a service fee equal to the operating cost plus a margin.
Post-merger, ASPI (through Noble) will control the board with 5 of 7 directors, plus the CEO seat. ENDRA will retain only one board seat. The companies will enter into ongoing commercial agreements including helium sales, shared services (ASPI providing admin services for cost-plus fees), and consolidated financial reporting requirements. This structure suggests ASPI will maintain operational and financial control over the combined entity despite the reverse-merger form.
Event · Exhibit 99.3
ASP Isotopes filed an 8-K with Exhibit 99.3, a presentation, but the exhibit content was not provided in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
EXHIBIT 99.3
The 8-K references Exhibit 99.3, labeled as a presentation. The actual content of the presentation was not included in the filing body provided, so the substance of what was disclosed cannot be determined from the available text. Investors should review the full exhibit on EDGAR to understand what information the company is presenting.
Event · Exhibit 99.2
ASP Isotopes announces proposed merger of subsidiary Noble Africa with ENDRA Life Sciences and concurrent $50M private placement financing.
Added in current filing · view on EDGAR →
ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes," “ASPI” or the "Company"), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, and ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or “NDRA”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced that ASP Isotopes’ wholly-owned subsidiary, Noble Africa LLC (“Noble Africa”), an intermediate holding company for Renergen Limited (“Renergen”), will merge with a subsidiary of ENDRA, with Noble Africa continuing as the surviving entity (the “Proposed Merger” and, together with the related transactions, the “Proposed Transactions”). Upon completion of the Proposed Transactions, the combined company plans to operate under the name Noble Africa Inc. and will apply to trade on The Nasdaq Stock Market LLC (“Nasdaq”) under the ticker symbol “NOBA.”
ASP Isotopes disclosed a proposed merger where its wholly-owned subsidiary Noble Africa (which holds Renergen Limited) will merge with a subsidiary of ENDRA Life Sciences. Noble Africa will be the surviving entity and plans to trade on Nasdaq under ticker NOBA. The transaction aims to establish Noble Africa as a publicly traded helium platform for Renergen's Virginia Gas Project.
Added in current filing · view on EDGAR →
Under the terms of the merger agreement, as of the closing of the Proposed Transactions, ASP Isotopes is expected to own approximately 89% of the combined company, the pre-closing ENDRA stockholders are expected to own approximately 3% of the combined company, and investors in the private placement financing (other than ASPI) are expected to own approximately 7% of the combined company.
Upon closing, ASP Isotopes will own approximately 89% of the combined company, pre-closing ENDRA stockholders will own approximately 3%, and private placement investors (excluding ASPI) will own approximately 7%. This structure gives ASP Isotopes controlling ownership while providing existing ENDRA shareholders with a minority stake.
Added in current filing · view on EDGAR →
The Proposed Transactions have received approvals by the Board of Directors of both ASP Isotopes and ENDRA and are expected to close in the third or fourth quarter of 2026, subject to the effectiveness of a registration statement to be filed with the U.S. Securities and Exchange Commission (the “SEC”) to register the securities to be issued in connection with the Proposed Transactions, approval by the stockholders of ENDRA and the satisfaction of other customary closing conditions.
Both boards of directors have approved the transaction, which is expected to close in Q3 or Q4 2026. Closing is subject to SEC registration statement effectiveness, ENDRA stockholder approval, and other customary conditions. The transaction requires regulatory filings and shareholder vote before completion.
Added in current filing · view on EDGAR →
The combined company plans to operate under the name Noble Africa Inc. and will initially be led by Paul E. Mann, Chief Executive Officer of Renergen and Chief Executive Officer and Executive Chairman of ASP Isotopes, and Nick Mitchell, Chief Operating Officer of Renergen and Co-Chief Operating Officer of ASP Isotopes. The combined company’s Board of Directors will consist of six directors selected by ASP Isotopes, including the Chief Executive Officer of the combined company, four non-executive directors designated by ASP Isotopes and one non-executive director designated by ENDRA.
The combined company will be led by Paul Mann (CEO) and Nick Mitchell (COO), both currently serving in leadership roles at ASP Isotopes and Renergen. The board will have six directors: the CEO plus four non-executive directors selected by ASP Isotopes and one non-executive director designated by ENDRA.
Event · Exhibit 99.1
ASP Isotopes Inc. (ASPI) filed an amended certificate of incorporation creating dual-class stock with 10:1 voting rights for Class B shares.
Added in current filing · view on EDGAR →
The total number of shares of capital stock that the Corporation is authorized to issue is 1,250,000,000 shares, divided into three classes consisting of (a) 1,000,000,000 shares of Class A common stock, par value $0.0001 per share (“Class A Common Stock”); (b) 200,000,000 shares of Class B common stock, par value $0.0001 per share (“Class B Common Stock” and, together with Class A Common Stock, the “Common Stock”); and (c) 50,000,000 shares of preferred stock, par value $0.0001 per share (“Preferred Stock”).
The company is adopting a dual-class common stock structure with Class A and Class B shares. Class B shares carry ten votes per share while Class A shares carry one vote per share, concentrating voting control. All existing common shares will automatically convert to Class A shares at the effective time.
Added in current filing · view on EDGAR →
Except as otherwise provided in this Certificate or otherwise required by applicable law, each holder of Class B Common Stock shall be entitled to ten votes for each share of Class B Common Stock held as of the applicable date on any matter that is submitted to a vote or to be acted on by consent of the stockholders of the Corporation.
Class B common stock carries 10-to-1 supervoting rights compared to Class A shares. This allows holders of Class B shares to maintain control with a minority economic stake, a common structure in founder-controlled companies but one that can reduce accountability to public shareholders.
Added in current filing · view on EDGAR →
The name of the corporation is Noble Africa Inc. (the “Corporation”).
The company is changing its legal name from ENDRA Life Sciences Inc. to Noble Africa Inc. This represents a complete rebranding that may signal a strategic shift in business focus or operations.
Added in current filing · view on EDGAR →
“ASP Permitted Holder” shall mean ASP Isotopes Inc. (“ASP”) and its Affiliates.
The certificate grants special transfer and control rights to ASP Isotopes Inc. and its affiliates, allowing them to transfer Class B shares among themselves without triggering automatic conversion to Class A shares. ASP Isotopes appears to be taking a controlling position in the company.
Added in current filing · view on EDGAR →
The Corporation hereby expressly elects not to be governed by Section 203 of the DGCL.
The company is opting out of Delaware's anti-takeover statute (Section 203) but implementing its own 3-year business combination restriction with a 66 2/3% approval threshold. This custom provision exempts ASP Isotopes and its transferees from interested stockholder restrictions, facilitating ASP's control while maintaining some protections against third-party acquirers.
Event · Item 8.01 — Other Events
ASPI disclosed background information on Renergen, a South African helium and LNG company, in connection with proposed merger transactions.
Added in current filing · verify on EDGAR →
Renergen is a South African energy company focused on the development and commercialization of helium and liquefied natural gas (“LNG”) resources. Through its operating platform, Renergen is positioned around the production of specialty gases and cleaner energy products that are expected to serve high-demand industrial, technology, medical, aerospace, semiconductor, and energy markets.
The 8-K provides detailed background on Renergen, describing its focus on helium production and LNG commercialization. Renergen develops helium resources for medical imaging, semiconductor manufacturing, aerospace, and other critical applications, while also producing LNG as a cleaner-burning energy alternative. This disclosure appears in connection with proposed merger transactions involving ASPI (formerly ENDRA), Renergen, and Noble.
Added in current filing · verify on EDGAR →
This Current Report on Form 8-K relates to the Proposed Transactions involving ENDRA, the Company, Renergen and Noble and may be deemed to be solicitation material in respect of the Proposed Transactions. In connection with the Proposed Transactions, ENDRA intends to file relevant materials with the SEC, including a registration statement on Form S-4 (the “Form S-4”) that will contain a proxy statement (the “Proxy Statement”) and prospectus.
The filing discloses proposed transactions involving ENDRA (now ASPI), Renergen, and Noble. ENDRA will file a Form S-4 registration statement containing a proxy statement and prospectus for stockholder approval. The disclosure includes extensive forward-looking statements about the merger structure, timing, expected benefits, and the combined company's anticipated Nasdaq listing and operations.
Added in current filing · verify on EDGAR →
the risk that Renergen does not receive funding from the U.S. DFC or Standard Bank SA or that such funding is delayed; risks related to ENDRA’s continued listing on Nasdaq until the Closing of the Proposed Transactions and the combined company’s ability to remain listed following the Closing
The filing identifies specific risks including potential delays or failure to receive funding from the U.S. Development Finance Corporation (DFC) or Standard Bank SA for Renergen's operations. It also highlights risks to ENDRA's Nasdaq listing both before and after the merger closes, which could affect the combined company's public market access.
Added in current filing · verify on EDGAR →
statements regarding the continuation of Renergen’s Virginia Gas Project and its funding timeline ... ; Renergen’s ability to obtain funding for its operations and future growth, including debt funding for Phase 2 of the Virginia Gas Project; Renergen’s ... ability to complete Phase 1 and 2 of the Virginia Gas Project
The filing references Renergen's Virginia Gas Project, a multi-phase development requiring additional funding. The project appears central to Renergen's helium and LNG production strategy, with completion of both Phase 1 and Phase 2 dependent on securing debt financing and other capital sources. Execution risk on this project could materially affect the combined company's operations.
Added in current filing · verify on EDGAR →
Renergen’s ability to comply with the terms of the loan and credit facilities of Renergen's subsidiary Tetra4
The filing identifies compliance risk with loan and credit facilities at Tetra4, a Renergen subsidiary. This suggests existing debt obligations that the combined company will inherit, with potential covenant or performance requirements that could constrain operations or require refinancing.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 26, 2026 · How we verify